Trial · NCT00123487
Results by group168
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 168
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment - Randomized Population | Dasatinib 140 mg QD | 48.0 | 95% Confidence Interval 42.3 to 53.8 | percentage of participants | |
| Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment - Randomized Population | Dasatinib 70 mg BID | 47.9 | 95% Confidence Interval 42.1 to 53.6 | percentage of participants | |
| Percent of Participants With Major Hematological Response (MaHR) With 2 Years of Follow-up From Date of Last Enrollment - Randomized Population | Dasatinib 140 mg QD | 50.7 | 95% Confidence Interval 44.9 to 56.4 | percentage of participants | |
| Percent of Participants With Major Hematological Response (MaHR) With 2 Years of Follow-up From Date of Last Enrollment - Randomized Population | Dasatinib 70 mg BID | 49.8 | 95% Confidence Interval 44.1 to 55.6 | percentage of participants | |
| Percent of Participants With Major Hematologic Response (MaHR) by Disease Group - Randomized Population | Dasatinib 140 mg QD | Accelerated Phase (n=158, 159) | 66.5 | 95% Confidence Interval 58.5 to 73.8 | percentage of participants |
| Percent of Participants With Major Hematologic Response (MaHR) by Disease Group - Randomized Population | Dasatinib 70 mg BID | Accelerated Phase (n=158, 159) | 67.9 | 95% Confidence Interval 60.1 to 75.1 | percentage of participants |
| Percent of Participants With Major Hematologic Response (MaHR) by Disease Group - Randomized Population | Dasatinib 140 mg QD | Myeloid Blast Phase (n=75,74) | 28.0 | 95% Confidence Interval 18.2 to 39.6 | percentage of participants |
| Percent of Participants With Major Hematologic Response (MaHR) by Disease Group - Randomized Population | Dasatinib 70 mg BID | Myeloid Blast Phase (n=75,74) | 28.4 | 95% Confidence Interval 18.5 to 40.1 | percentage of participants |
| Percent of Participants With Major Hematologic Response (MaHR) by Disease Group - Randomized Population | Dasatinib 140 mg QD | Lymphoid Blast Phase (n=33,28) | 42.4 | 95% Confidence Interval 25.5 to 60.8 | percentage of participants |
| Percent of Participants With Major Hematologic Response (MaHR) by Disease Group - Randomized Population | Dasatinib 70 mg BID | Lymphoid Blast Phase (n=33,28) | 32.1 | 95% Confidence Interval 15.9 to 52.4 | percentage of participants |
| Percent of Participants With Major Hematologic Response (MaHR) by Disease Group - Randomized Population | Dasatinib 140 mg QD | Ph+ Acute Lymphoblastic Leukemia (n=40,44) | 37.5 | 95% Confidence Interval 22.7 to 54.2 | percentage of participants |
| Percent of Participants With Major Hematologic Response (MaHR) by Disease Group - Randomized Population | Dasatinib 70 mg BID | Ph+ Acute Lymphoblastic Leukemia (n=40,44) | 31.8 | 95% Confidence Interval 18.6 to 47.6 | percentage of participants |
| Median Time to Major Hematologic Response (MaHR) - Randomized Population | Dasatinib 140 mg QD | 6 Months | 1.9 | 95% Confidence Interval 1.8 to 1.9 | Months |
| Median Time to Major Hematologic Response (MaHR) - Randomized Population | Dasatinib 70 mg BID | 6 Months | 1.9 | 95% Confidence Interval 1.5 to 2.0 | Months |
| Median Time to Major Hematologic Response (MaHR) - Randomized Population | Dasatinib 140 mg QD | 2 Years | 1.9 | 95% Confidence Interval 1.8 to 1.9 | Months |
| Median Time to Major Hematologic Response (MaHR) - Randomized Population | Dasatinib 70 mg BID | 2 Years | 1.9 | 95% Confidence Interval 1.6 to 2.1 | Months |
| Median Duration of a Major Hematologic Response (MaHR) in Those Participants Who Achieved a MaHR During the Study | Dasatinib 140 mg QD | 21.1 | 95% Confidence Interval 14.4 to 30.7 | Months | |
| Median Duration of a Major Hematologic Response (MaHR) in Those Participants Who Achieved a MaHR During the Study | Dasatinib 70 mg BID | 24.7 | 95% Confidence Interval 19.5 to 35.6 | Months | |
| Percent of Participants With Overall Hematologic Response - Randomized Population | Dasatinib 140 mg QD | 6 Months | 59.2 | 95% Confidence Interval 53.4 to 64.7 | percentage of participants |
| Percent of Participants With Overall Hematologic Response - Randomized Population | Dasatinib 70 mg BID | 6 Months | 57.4 | 95% Confidence Interval 51.6 to 63.0 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00123487/results